Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genaissance Pharmaceuticals (GNSC) -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (11)	1/11/2001 7:08:30 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 183

Biotechs Face New Year Hangover From IPO Overhang By Dane Hamilton Staff Reporter: TheStreet.com 12/26/00 11:40 AM ET Venture capitalists could be dumping a blizzard of biotech stocks onto the market early next year, dampening demand for the risky paper. That's when a record number of six-month lockups expire for the bumper crop of biotech IPOs that hit the market this year. After lockups expire, early investors and other insiders can sell the shares they may have picked up for pennies, generating hefty gains. According to Lehman Brothers, lockups on 22 biotech IPOs are slated to expire between Jan. 13 and Feb. 10, the largest number ever. If the early venture capital investors offer all their stock, more than 367 million shares will hit the market <snip> IPO date Name Symbol end Lockup # shares 8/1/00 Genaissance GNSC 1/28/01 15.370M